Canopy Growth Relaunches Tweed in Germany with MTL Cannabis Strains

Tweed Returns to Germany with MTL Portfolio

Canopy Growth reintroduced Tweed to German pharmacies on May 30, 2026, pairing the legacy brand with its MTL (Montréal) cultivar line. The company withdrew Tweed from European distribution in 2022 amid a global restructuring that saw Canopy exit multiple international markets to stem losses exceeding CAD $3 billion over three fiscal years.

The relaunch centers on MTL strains, a Quebec-focused brand Canopy acquired in 2019 and has since positioned as a craft-adjacent offering in Canada's recreational market. Germany's medical framework doesn't permit recreational sales. That limits Tweed's distribution to the country's approximately 1,800 licensed pharmacies that dispense cannabis under physician prescription.

Canopy hasn't disclosed which MTL strains will anchor the German rollout. In Canada, the MTL portfolio includes cultivars such as Sage N Sour, Pineapple Express, and Cookies & Cream, typically sold in 3.5g and 7g dried-flower formats.

Germany's Medical Market Expansion Creates Reentry Opportunity

Germany's medical cannabis patient base grew 47% year-over-year in 2025, reaching an estimated 340,000 registered patients by year-end. That growth trajectory positions Germany to surpass Canada as the world's second-largest legal cannabis market by patient count, trailing only the United States.

The country's Bundestag passed legislation in April 2024 legalizing limited home cultivation and social-club distribution, but those provisions remain in pilot phase. Medical sales continue to dominate. Germany imported 22.4 metric tons of medical cannabis in 2025, up from 15.1 tons in 2024, according to the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).

Key drivers of German demand include:

• Expanded insurance reimbursement for chronic pain and PTSD indications
• Physician adoption rates climbing to 12,000 prescribers nationwide
• Domestic cultivation licenses awarded to four German producers, reducing reliance on Canadian and Dutch imports

Canopy's reentry places it in direct competition with Tilray Brands, Aurora Cannabis, and Aphria (now part of Tilray), all of which maintained continuous German distribution through the 2022–2024 downturn.

Canopy's European Strategy After Years of Contraction

The Tweed relaunch marks Canopy's first major European product expansion since the company shuttered operations in South Africa, Colombia, and Lesotho between 2022 and 2023. Canopy CEO David Klein told investors in a March 2026 earnings call that international medical markets would receive "selective investment" only where margin profiles exceeded 30% gross.

Germany qualifies under that threshold. Wholesale prices for premium dried flower in German pharmacies averaged €12–€15 per gram in Q1 2026, compared to CAD $4.20–$5.80 per gram in Canada's saturated recreational market. Canopy hasn't disclosed its German pricing structure for MTL strains.

The company's German distribution partner remains unnamed in public filings. Canopy previously partnered with CC Pharma, a Tilray subsidiary, for European logistics before that arrangement ended in 2022. Industry sources suggest Canopy may be working with AMP German Cannabis Group, a Hamburg-based importer that handles third-party brands, though neither company has confirmed the relationship.

What the Tweed-MTL Pairing Signals for Brand Architecture

Canopy's decision to co-brand Tweed with MTL reflects a shift away from standalone legacy brands toward portfolio segmentation by price tier and cultivar origin. In Canada, Canopy has collapsed more than 20 brands acquired between 2017 and 2020 into four active lines: Tweed (value), Doja (mid-tier), 7ACRES (premium), and MTL (craft).

Germany's market doesn't recognize recreational brand equity. That means Tweed's heritage as Canada's first federally licensed producer carries limited consumer weight. Pairing it with MTL allows Canopy to emphasize strain specificity and terpene profiles, attributes that resonate with Germany's medically oriented patient base.

For context on Germany's evolving regulatory landscape and its impact on international suppliers, see the CannIntel topic hub on Germany's medical cannabis market.

Canopy hasn't announced plans to introduce other brands—such as Spectrum Therapeutics or Storz & Bickel vaporizers—to the German relaunch. The company sold its BioSteel sports-nutrition brand in 2023 and divested its U.S. CBD brand, This Works, in 2024.